dabigatran dose 2

ApprovedSmall molecule

Boehringer Ingelheim

dabigatran dose 2 is one of 233 small molecule programs targeting Venous Thromboembolism. It is currently in Approved.

Indications

108

Total Trials

Active Trials

232

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

StrokeActive, not recruiting

Venous ThrombosisActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Intracranial HemorrhageActive, not recruiting

Pulmonary EmbolismActive, not recruiting

Total Hip ArthroplastyActive, not recruiting

Atrial FibrillationActive, not recruiting

SclerodermaActive, not recruiting

Venous ThromboembolismPhase 3

Active, not recruiting

StrokePhase 3

Active, not recruiting

Venous ThrombosisPhase 3

Active, not recruiting

Acute Coronary SyndromePhase 2

Active, not recruiting

Intracranial HemorrhagePreclinical

Active, not recruiting

Pulmonary EmbolismApproved

Active, not recruiting

Total Hip ArthroplastyPhase 3

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

SclerodermaPhase 1

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

dabigatran dose 2

Boehringer Ingelheim

Approved

2 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Savella

AbbVie

Preclinical

1 5

Folvite

Eli Lilly

Preclinical

1 6

Pradaxa

Boehringer Ingelheim

Preclinical

3 7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Venous Thrombosis

NCT06551402

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Q3 2027

Post-ApprovalActive, not recruiting

Atrial Fibrillation

NCT04045093

Q4 2027

Post-ApprovalActive, not recruiting

Atrial Fibrillation

NCT03129490

Q1 2029

Post-ApprovalActive, not recruiting

Venous Thromboembolism

NCT03129555

Clinical

Trials by Indication[1]

Atrial Fibrillation14 trials

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Active, not recruiting·HHerlev and Gentofte Hospital·Phase 4·NCT03129490·11,000 enrolled

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01136408·174 enrolled

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

Terminated·UUniversity of Utah·Phase 4·NCT01546883·14 enrolled

Show 11 more trials

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03026556·42,534 enrolled

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)

Unknown status·UUral State Medical University·Phase 4·NCT03975062·400 enrolled

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

Unknown status·NNational Cheng-Kung University Hospital·Phase 4·NCT02666157·3,672 enrolled

Dabigatran for Mitral Stenosis Atrial Fibrillation

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT04045093·370 enrolled

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Unknown status·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT03183843·40 enrolled

The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT02646267·210 enrolled

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02240667·1,506 enrolled

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

Completed·WWuhan Asia Heart Hospital··NCT03280641·1,194 enrolled

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Completed·IIntermountain Health Care, Inc.·Phase 4·NCT03061006·101 enrolled

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

Terminated· Bayer logo

Bayer··NCT03715725·70,000 enrolled

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00808067·5,897 enrolled

Venous Thromboembolism8 trials

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00291330·2,564 enrolled

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00168818·3,494 enrolled

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Active, not recruiting·HHerlev and Gentofte Hospital·Phase 4·NCT03129555·5,000 enrolled

Show 5 more trials

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00680186·2,589 enrolled

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00152971·2,615 enrolled

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Unknown status·TThe University of Hong Kong·Phase 3·NCT03240120·99 enrolled

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01895777·267 enrolled

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00246025·512 enrolled

Female5 trials

Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171013·66 enrolled

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Completed· Bayer logo

Bayer·Phase 1·NCT05471817·20 enrolled

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171520·66 enrolled

Show 2 more trials

Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171052·24 enrolled

Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171481·66 enrolled

Interaction5 trials

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Completed· Bayer logo

Bayer·Phase 1·NCT03237416·15 enrolled

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01734772·48 enrolled

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01306162·36 enrolled

Show 2 more trials

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01595854·36 enrolled

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02568397·60 enrolled

Oral5 trials

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171572·28 enrolled

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171468·48 enrolled

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171455·10 enrolled

Show 2 more trials

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02044367·54 enrolled

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03070171·160 enrolled

46 more indications

Single Dose5 trials

Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171507·24 enrolled

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02170987·40 enrolled

Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171026·24 enrolled

Show 2 more trials

Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02170675·24 enrolled

Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02173717·24 enrolled

Venous thrombosis3 trials

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Recruiting·KKafrelsheikh University·Phase 3·NCT06551415·200 enrolled

Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis

Recruiting·KKafrelsheikh University·Phase 3·NCT06551402·200 enrolled

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Unknown status·—·Phase 3·NCT03217448·80 enrolled

Children3 trials

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01773174

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05536791

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01083732·18 enrolled

Tics3 trials

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171624·42 enrolled

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Completed·CCorcept Therapeutics·Phase 1·NCT05347979·30 enrolled

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Not yet recruiting·TThe Affiliated Hospital Of Guizhou Medical University··NCT06387407·30 enrolled

Statin3 trials

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT04257032·28 enrolled

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT05480475·24 enrolled

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Completed· Bayer logo

Bayer·Phase 1·NCT06329895·15 enrolled

Treatment2 trials

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT01184989·142 enrolled

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00157248·361 enrolled

Midazolam2 trials

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07190430·16 enrolled

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05438303·59 enrolled

Adult2 trials

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT05673889·24 enrolled

Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults

Recruiting·PPeking University Third Hospital·N/A·NCT06360055·12 enrolled

Stroke2 trials

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02239120·5,390 enrolled

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01227629·502 enrolled

Prevention2 trials

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02197416·214 enrolled

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00558259·1,353 enrolled

Clopidogrel1 trial

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171598·44 enrolled

MPA1 trial

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02710630·35 enrolled

Elderly Participants1 trial

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01379300·42 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions

Not yet recruiting·IInternational Bio service·Phase 1·NCT06441916·60 enrolled

Prophylaxis1 trial

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

Heart1 trial

Dabigatran Etexilate in Patients With Mechanical Heart Valves

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01452347·328 enrolled

Drug Interactions1 trial

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

Completed·—·Phase 1·NCT05959447·45 enrolled

Metformin1 trial

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06504862·32 enrolled

Renal Impairment1 trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02182024·35 enrolled

Ablation1 trial

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02348723·678 enrolled

T2DM1 trial

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD

Unknown status·IIrina Ermolaeva·Phase 4·NCT03789695·200 enrolled

Intracranial Hemorrhage1 trial

Registration of Idarucizumab for Patients with IntraCranial Hemorrhage

Completed·UUniversity Hospital, Essen··NCT04062097·104 enrolled

Adolescent1 trial

Safety and Tolerability of Dabigatran Etexilate in Adolescents

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00844415·9 enrolled

TIA1 trial

Validation of Predictors of OAC Initiation Using EMR Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03006341·140,187 enrolled

Knee Surgery1 trial

RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00168805·2,101 enrolled

Trial1 trial

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

Terminated·JJohannes Gutenberg University Mainz·Phase 2·NCT02256683·64 enrolled

Total Hip Arthroplasty1 trial

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00657150·2,055 enrolled

Antithrombotic1 trial

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

Acute Coronary Syndrome1 trial

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00621855·1,878 enrolled

Renal Disease1 trial

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01711853·19 enrolled

Scleroderma1 trial

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Completed·MMedical University of South Carolina·Phase 1·NCT02426229·15 enrolled

Atrial Appendage1 trial

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

Completed·VVanderbilt University Medical Center·Phase 4·NCT03539055·100 enrolled

Overweight or Obese1 trial

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05788328·16 enrolled

Fruquintinib1 trial

Fruquintinib DDI Study With P-gp and BCRP Substrates

Completed·HHutchmed·Phase 1·NCT05368805·32 enrolled

Elderly1 trial

Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects

Unknown status·DDongyang Liu·N/A·NCT05715658·36 enrolled

Efficacy and Safety1 trial

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02913326·120 enrolled

Moderate Hepatic Impairment1 trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02170571·24 enrolled

Concentration1 trial

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03086356·12 enrolled

Pulmonary Embolism1 trial

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 4·NCT02979561·200 enrolled

ART1 trial

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04208061·28 enrolled

Absorption1 trial

Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171546·42 enrolled

Haemodialysis1 trial

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01241539·7 enrolled

Dialysis Patients1 trial

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Completed·NNova Scotia Health Authority·Phase 1·NCT01590823·10 enrolled

Enoxaparin1 trial

Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171559·29 enrolled

Anticoagulant Therapy1 trial

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00262600·18,113 enrolled

Unspecified9 trials

A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06791187·14 enrolled

Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171585·20 enrolled

A Study of Lasmiditan in Healthy Volunteers

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT04749914·97 enrolled

Show 6 more trials

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171611·30 enrolled

Bioequivalence of Two Different Capsule Types of Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01290757·180 enrolled

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03143166·36 enrolled

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03492437·20 enrolled

Follow on Study From RE-ALIGN

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01505881·158 enrolled

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02164864·2,725 enrolled

Sources

References

[1]
ClinicalTrials.gov — 108 trial records for dabigatran dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dabigatran dose 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dabigatran dose 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

dabigatran dose 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q1 2029

Trials by Indication[1]

Atrial Fibrillation14 trials

Venous Thromboembolism8 trials

Female5 trials

Interaction5 trials

Oral5 trials

Single Dose5 trials

Venous thrombosis3 trials

Children3 trials

Tics3 trials

Statin3 trials

Treatment2 trials

Midazolam2 trials

Adult2 trials

Stroke2 trials

Prevention2 trials

Clopidogrel1 trial

MPA1 trial

Elderly Participants1 trial

Fasting Conditions1 trial

Prophylaxis1 trial

Heart1 trial

Drug Interactions1 trial

Metformin1 trial

Renal Impairment1 trial

Ablation1 trial

T2DM1 trial

Intracranial Hemorrhage1 trial

Adolescent1 trial

TIA1 trial

Knee Surgery1 trial

Trial1 trial

Total Hip Arthroplasty1 trial

Antithrombotic1 trial

Acute Coronary Syndrome1 trial

Renal Disease1 trial

Scleroderma1 trial

Atrial Appendage1 trial

Overweight or Obese1 trial

Fruquintinib1 trial

Elderly1 trial

Efficacy and Safety1 trial

Moderate Hepatic Impairment1 trial

Concentration1 trial

Pulmonary Embolism1 trial

ART1 trial

Absorption1 trial

Haemodialysis1 trial

Dialysis Patients1 trial

Enoxaparin1 trial

Anticoagulant Therapy1 trial

Unspecified9 trials

References

Drug Info

Quick Facts

Related News